Alembic Pharma News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Alembic Pharma from all sources in a single place.

12 Jan 2026

780.35

-1.21%

Alembic Pharmaceuticals gets USFDA tentative nod for generic cancer treatment drug

Business Line

The tentative approval granted by the US Food & Drug Administration (USFDA) is for its supplemental abbreviated new drug application (sANDA) Bosutinib tablets of strength 400 mg, Alembic said in a regulatory filing

Alembic Pharma has lost -24.27% in the last 6 Months

Alembic Pharmaceuticals Ltd.

12 Jan 2026

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited announces USFDA Tentative approval for Bosutinib Tablets, 400 mg.

pdf

Alembic Pharmaceuticals Ltd.

05 Jan 2026

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please find attached herewith the Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st December, 2025

pdf

Alembic Pharmaceuticals Ltd.

26 Dec 2025

780.35

-1.21%

SAST

Alembic Pharmaceuticals Ltd - 533573 - Closure of Trading Window

BSE India

Intimation of Closure of Trading Window.

pdf

Alembic Pharmaceuticals Ltd.

25 Dec 2025

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith Newspaper Publication related to notice of Loss of Share Certificate.

pdf

Alembic Pharmaceuticals Ltd.

18 Dec 2025

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited announces USFDA approval for Travoprost Ophthalmic Solutions

pdf

Alembic Pharmaceuticals Ltd.

16 Dec 2025

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure …

BSE India

Please find attached herewith announcement under Regulation 30 of SEBI (LODR) Regulations, 2015

pdf

Alembic Pharmaceuticals Ltd.

15 Dec 2025, 04:37PM

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached Newspaper Publication of Special Window for re-lodgement of transfer of physical shares.

pdf

Alembic Pharmaceuticals Ltd.

12 Dec 2025

780.35

-1.21%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached herewith a copy of advertisement elated to notice of loss of equity share certificate published by Company.

pdf

Alembic Pharmaceuticals Ltd.

11 Dec 2025

780.35

-1.21%

Alembic gets USFDA nod for generic eye infection treatment suspension

Business Standard

Alembic Pharmaceuticals Ltd on Thursday said it has received final approval from the US health regulator for its generic version of Loteprednol Etabonate and Tobramycin ophthalmic suspension used for treatment of eye infection. The approval granted by the US Food & Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) Loteprednol Etabonate and Tobramycin Ophthalmic Suspension of strength 0.5 per cent/0.3 per cent (5 mL and 10 mL), Alembic Pharmaceuticals Ltd said in a regulatory filing. Alembic was granted a Competitive Generic Therapy (CGT) designation for this application. With this approval, Alembic is eligible for 180 days of CGT exclusivity upon commercialisation, it added. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5 per cent/0.3 per cent, of Bausch & Lomb Incorporated, the company said. Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5 per cent/0.3 per cent, is...

Alembic Pharmaceutic.. has an average target of 1028.50 from 4 brokers.

Alembic Pharmaceuticals gets USFDA nod for generic eye infection treatment suspension

Business Line | 11 Dec 2025

Is Alembic Pharmaceuticals Ltd. worth buying?

241 Votes:

Buy 83.82%

Sell 8.3%

Hold 7.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf